Transition Therapeutics Inc.

Transition Therapeutics Inc. is a fully integrated biopharmaceutical company with a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications. The focus of the corporate business is to discover and advance lead molecules to the most valuable and competitive targets in the industry using our state-of-the-art drug discovery engine, to accelerate the development of multiple products for large disease indications and to generate shareholder value through partnership with major pharmaceutical companies.

Contact Details: MaRS Centre, Heritage Building 101 College Street, Suite 220 Toronto Ontario M5G 1L7 Canada Tel: 416-260-7770 Fax: 416-260-2886 Email: info@transitiontherapeutics.com WWW: www.transitiontherapeutics.com/

Loading...

Recent Publications by Transition Therapeutics Inc.:
Automated multiple ligand screening by frontal affinity chromatography-mass spectrometry (FAC-MS). High-throughput screening (HTS) efforts to discover "hits" typically rely...	21st April, 2007	Transition Therapeutics Inc, Drug Discovery Group, Toronto, Ontario,	J Biomol Screen. 2007 Mar;12(2):167-74. Epub 2007 Jan 11. DOI Direct Link

Press Releases on Transition Therapeutics Inc.:
Oncolytics Biotech(R) Inc. Announces 2009 Third Quarter Results	5th November, 2009	Oncolytics Biotech Inc.	CALGARY, Nov. 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and nine
Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations	18th June, 2009	Transition Therapeutics Inc.	TORONTO, June 18 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), is pleased to announce that Ms. Laura Agensky has
Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results	13th May, 2009	Transition Therapeutics Inc.	TORONTO, May 13 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST	12th May, 2009	Transition Therapeutics Inc.	TORONTO, May 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 13,
Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results	5th May, 2009	Oncolytics Biotech Inc.	CALGARY, May 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three-month

BioNews Results for Transition Therapeutics Inc.:
Transition Therapeutics Announces First Quarter Fiscal 2010 Financial Results	Yahoo! Canada:  Nov 10 2009 9:47PM Matching: transition therapeutics inc
Transition Therapeutics Announces First Quarter Fiscal 2010 Financial Results	Interest!ALERT:  Nov 10 2009 11:50PM Matching: transition therapeutics inc
Transition Therapeutics Announces First Quarter Fiscal 2010 Financial Results	NewsBlaze:  Nov 10 2009 9:19PM Matching: transition therapeutics inc
Transition Therapeutics Announces First Quarter Fiscal 2010 Financial Results	Therapeutics Daily:  Nov 10 2009 10:22PM Matching: transition therapeutics inc
Transition Therapeutics Announces First Quarter Fiscal 2010	GlobeNewswire via MSN Money:  Nov 10 2009 9:49PM Matching: transition therapeutics inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more Transition Therapeutics Inc. news.

Transition Therapeutics Inc. Patents:
US Patent No.	Title
7595294	Vasoactive intestinal polypeptide pharmaceuticals
7566691	Vasoactive intestinal polypeptide pharmaceuticals
7026355	Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
6911429	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
6908611	Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
→View more Transition Therapeutics Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 319 times since April 2007, the link to the organisation's website has been followed 63 times

Recent Search Terms used to find this page: transition therapeutics inc | .

Search for more companies in Toronto

Search for more companies in Ontario

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Transition Therapeutics Inc.